Esophageal Cancer Clinical Trial
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Summary
RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment.
PURPOSE: This randomized phase II trial is studying PET scan imaging in assessing response in patients with esophageal cancer receiving combination chemotherapy.
Full Description
OBJECTIVES:
Primary
To induce a complete pathologic response (pCR) rate of 20% in positron emission tomography (PET) scan non-responders treated with either induction FOLFOX or carboplatin/paclitaxel, who then crossover to the other regimen during radiotherapy.
Secondary
To compare PET/CT response between induction treatment arms.
To compare pCR between induction treatment arms among PET/CT scan responders.
To directly compare pCR between induction treatment arms among non-responders if both treatment regimens are found to be efficacious.
To determine 8-month progression-free survival (PFS) in PET/CT scan responders, and in non-responders treated with alternative crossover chemoradiotherapy.
Estimate the PFS and overall survival (OS) curves, overall and among PET responders and PET/CT non-responders by induction treatment.
To determine the rate of postoperative anastomotic leak after neoadjuvant chemotherapy followed by chemoradiation.
To evaluate immunohistochemistry and RT-PCR of ERCC1, and genetic polymorphisms of ERCC1, XPD, and XRCC1.
To evaluate status and levels of methylation of nine candidate biomarker genes as well as expression levels of selected specific microRNAs, which will be correlated with chemoradiation response.
To compare the quality of life (QOL) of responders and nonresponders (as determined by PET/CT scanning) to presurgical treatment for esophageal cancer, in terms of global QOL, physical symptoms, physical functioning, and emotional well-being.
To examine the association between OS and QOL in esophageal cancer patients treated with chemotherapy, chemoradiation therapy, and surgery.
OUTLINE: This is a multicenter study. Patients are stratified according to T-stage (T1-2 vs T3-4) and nodal status (N0 vs N+). Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive modified FOLFOX-6 therapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-5. Treatment repeats every 14 days for 3 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreased by ≥ 35%) receive 3 additional courses of FOLFOX-6 therapy and undergo concurrent radiotherapy (RT) (3D-conformal or intensity-modulated) once daily, 5 days a week, for approximately 6 weeks. Patients without responsive disease (tumor metabolic activity did not decrease by 35%) cross over to arm II during RT.
Arm II: Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 2 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreases ≥ 35%) continue to receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly for 5 weeks and undergo RT (3D-conformal or intensity-modulated) once a day, 5 days a week, for approximately 6 weeks. Patients without responsive disease (metabolic activity did not decrease by 35%) cross over to arm I during RT.
Within 4-10 weeks after completion of neoadjuvant chemoradiotherapy, patients undergo surgery at the discretion of the treating team.
Patients may undergo blood sample collection at baseline and periodically during study for correlative studies. Patients may also complete quality-of-life questionnaires at baseline and periodically during study.
After completion of study therapy, patients are followed up periodically for 5 years.
Eligibility Criteria
Surgically resectable, histologically confirmed esophageal adenocarcinoma, including Siewert gastroesophageal (GE) junction adenocarcinomas types 1 and 2
T1N1-3M0 or T2-4NanyM0 as determined by endoscopic ultrasound (EUS) and PET/CT (histologic confirmation of lymph involvement is not required); all disease (tumor and nodes) must be both surgically resectable and capable of containment in a radiotherapy field; no T4 tumor with clear evidence of invasion of the vertebral column, heart, great vessels, or tracheobronchial tree
All patients must have locoregional staging determined by endoscopic ultrasound (EUS) if technically feasible; endoscopy reports or subsequent gastrointestinal (GI) clinic note should clearly state both the T and N stage
No evidence of distant metastases (as determined by EUS or PET/CT)
Patients with cervical, supraclavicular, or other nodal disease that is either not included in the radiation field or is not able to be resected at the time of esophagectomy are not eligible
Patient must have pre-resection tissue available for central pathology review, in case that the patient has a pCR at the time of surgical resection to confirm diagnosis
Patients must have an fludeoxyglucose F 18 (FDG)-avid tumor with a maximum standard uptake value (SUVmax) of >= 5.0 on baseline PET/CT scan of primary tumor; baseline PET/CT scan should be performed; if it is necessary to repeat baseline PET/CT scan, reimbursement information is available
No prior malignancy within 5 years of registration, with the exception of basal or squamous cell skin cancers, or in situ bladder or cervical cancer; patients with prior malignancy treated with surgery only and disease free for more than 5 years are eligible; however, no prior thoracic radiation therapy (RT) or abdominal RT or chemotherapy allowed
No known contraindication to the use of fluorouracil, taxanes, or platinum compounds
No history of severe hypersensitivity reaction to Cremophor EL
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Patient must be non-pregnant and non-nursing; women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 72 hours prior to randomization; women of child-bearing potential include any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea >= 12 consecutive months; or women on hormone replacement therapy [HRT] with documented serum follicle stimulating hormone [FSH] level > 35mIU/mL); even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential
Absolute neutrophil count (ANC) >= 1,500/μL
Platelet count >= 100,000/μL
Bilirubin =< 1.5 times upper limit of normal (ULN)
Calculated creatinine clearance >= 60 mL/min
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 times ULN
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 60 Locations for this study
Mountain View California, 94040, United States
Palo Alto California, 94301, United States
San Francisco California, 94115, United States
New Haven Connecticut, 06520, United States
Lewes Delaware, 19958, United States
Newark Delaware, 19713, United States
Washington District of Columbia, 20007, United States
'Aiea Hawaii, 96701, United States
'Aiea Hawaii, 96701, United States
Honolulu Hawaii, 96813, United States
Honolulu Hawaii, 96813, United States
Honolulu Hawaii, 96813, United States
Honolulu Hawaii, 96817, United States
Honolulu Hawaii, 96817, United States
Honolulu Hawaii, 96826, United States
Kailua Hawaii, 96734, United States
Lihue Hawaii, 96766, United States
Chicago Illinois, 60611, United States
Chicago Illinois, 60612, United States
Chicago Illinois, 60637, United States
Peoria Illinois, 61615, United States
Peoria Illinois, 61615, United States
Urbana Illinois, 61801, United States
Ames Iowa, 50010, United States
Sioux City Iowa, 51101, United States
Elkton Maryland, 21921, United States
Boston Massachusetts, 02114, United States
Ann Arbor Michigan, 48106, United States
Saint Paul Minnesota, 55101, United States
Saint Paul Minnesota, 55102, United States
Jackson Mississippi, 39216, United States
Pascagoula Mississippi, 39581, United States
Saint Louis Missouri, 63110, United States
Billings Montana, 59107, United States
Omaha Nebraska, 68114, United States
New Brunswick New Jersey, 08903, United States
Voorhees New Jersey, 08043, United States
New York New York, 10016, United States
New York New York, 10029, United States
New York New York, 10065, United States
Syracuse New York, 13210, United States
Chapel Hill North Carolina, 27599, United States
Charlotte North Carolina, 28232, United States
Charlotte North Carolina, 28233, United States
Statesville North Carolina, 28677, United States
Fargo North Dakota, 58102, United States
Fargo North Dakota, 58122, United States
Columbus Ohio, 43210, United States
Oklahoma City Oklahoma, 73104, United States
Monroeville Pennsylvania, 15146, United States
Natrona Heights Pennsylvania, 15065, United States
Philadelphia Pennsylvania, 19107, United States
Philadelphia Pennsylvania, 19140, United States
Pittsburgh Pennsylvania, 15212, United States
Pittsburgh Pennsylvania, 15232, United States
Spartanburg South Carolina, 29303, United States
Berlin Vermont, 05602, United States
Burlington Vermont, 05401, United States
Eau Claire Wisconsin, 54701, United States
Marshfield Wisconsin, 54449, United States
Marshfield Wisconsin, 54449, United States
Minocqua Wisconsin, 54548, United States
Rhinelander Wisconsin, 54501, United States
Rice Lake Wisconsin, 54868, United States
Stevens Point Wisconsin, 54481, United States
Stevens Point Wisconsin, 54481, United States
Weston Wisconsin, 54476, United States
Weston Wisconsin, 54476, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.